Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2015-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this survey is to examine the safety and efficacy of long-term use of alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus determined as warranting combination therapy with alogliptin benzoate and pioglitazone hydrochloride

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeda
• Treatments: Alogliptin; Pioglitazone

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes mellitus

Exclusion Criteria:

• Patients meeting any of the following criteria will be excluded:

1. Patients with current cardiac failure or a past history of cardiac failure

2. Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus

3. Patients with serious hepatic dysfunction

4. Patients with serious renal dysfunction

5. Patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury

6. Patients with a history of hypersensitivity to any ingredients of Alogliptin/Pioglitazone

7. Pregnant or possibly pregnant women